eed inhibitor apg-5918
Generic: EED Inhibitor APG-5918
eed inhibitor apg-5918: 1 clinical trial tracked.
eed inhibitor apg-5918 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about eed inhibitor apg-5918, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1, Ascending Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of APG-5918 in Healthy Volunteers and Patients With Anemia.
Primary endpoint: Treatment-Emergent Adverse Events (TEAEs)
InterventionalRandomizeddouble105 targetStarted 2023-03Completion 2028-072 sites · ChinaAscentage Pharma Group Inc.